1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. News
  7. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lipocine Chief Financial Officer is Retiring

01/21/2022 | 04:18pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
LIPOCINE INC. -3.15% 0.88 Delayed Quote.-6.46%
PRINCIPAL FINANCIAL GROUP, INC. -1.08% 69.8 Delayed Quote.-4.27%
All news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12LIPOCINE INC. : Financial Statements and Exhibits (form 8-K)
AQ
05/12LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Financials (USD)
Sales 2022 2,21 M - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,47x
Yield 2022 -
Capitalization 82,0 M 82,0 M -
Capi. / Sales 2022 37,2x
Capi. / Sales 2023 11,0x
Nbr of Employees 13
Free-Float 97,5%
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,93 $
Average target price 3,67 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Mahesh V. Patel Chairman, President, Chief Executive Officer & CFO
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Jeffrey Arvin Fink Independent Director
Jill M. Jene Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-6.46%82
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666